Age-related Macular Degeneration Market - By Product, By Disease Type, By Age Group, By Distribution Channel - Global Forecast, 2024 – 2032

Age-related Macular Degeneration Market Size

The global age-related macular degeneration market size was valued at around USD 10.4 billion in 2023 and is estimated to grow at 9.8% CAGR from 2024 to 2032. Age-related macular degeneration (AMD) is an eye condition that can hinder central vision. It arises when aging damages the macula, the eye's region responsible for sharp, direct vision. The macula resides within the retina, the light-sensitive tissue located at the back of the eye.

Driven by new product launches, a strong product pipeline, and rising AMD prevalence rates, the AMD market is poised for significant growth. The Population Reference Bureau projects that the number of Americans aged 65 and older will surge from 58 million in 2022 to 82 million by 2050, marking a 47% increase. This demographic trend signals an unprecedented aging wave in the U.S. population.
 

Many older adults grapple with chronic diseases like diabetes and hypertension, heightening their AMD risk. The National Council on Aging highlights that around 95% of older adults have at least one chronic condition, with 80% managing two or more. Given the rising prevalence of these conditions, there's a pressing need for effective management strategies, including AMD treatment. This situation emphasizes the necessity for holistic healthcare approaches for older adults, aiming to manage multiple chronic conditions and mitigate AMD risk.
 

Research and development in AMD therapies are broadening patient treatment options. These advancements encompass novel ophthalmology drugs, valued at USD 31 billion in 2023, including anti-VEGF agents, corticosteroids, and gene therapies. The American Academy of Ophthalmology notes that anti-VEGF treatment enhances vision in about one-third of recipients and stabilizes it for roughly 90%. Such improved treatment outcomes, fueled by these innovations, are set to propel market growth. As research advances, these emerging therapies not only promise to uplift the quality of life for AMD patients but also hold potential in decelerating disease progression.

Age-related Macular Degeneration Market Trends

• Increased awareness of Age-related Macular Degeneration (AMD) among both healthcare professionals and the general public has led to more frequent screenings and earlier detections. Public health campaigns and educational initiatives are motivating individuals to pursue preventive care, subsequently driving up the demand for AMD treatments. The World Health Organization (WHO) reported that in 2020, AMD accounted for 8.7% of global blindness, impacting around 196 million individuals. Such figures highlight the critical need for heightened awareness and early detection in alleviating the global AMD burden.
   
• Government-led programs and healthcare initiatives focused on enhancing eye health and broadening access to ophthalmic care are bolstering the AMD market. Financial backing for research and awareness initiatives not only aids in crafting new therapies but also champions the importance of routine eye check-ups. This trend underscores public health entities' dedication to tackling AMD-related challenges and pushing for advanced treatment avenues.
   
• Pharmaceutical firms and healthcare entities are rolling out patient assistance and support programs, significantly enhancing treatment accessibility. These initiatives guide patients through insurance and financial hurdles, ensuring they stick to their prescribed therapies. By mitigating financial obstacles, these support systems are pivotal in guaranteeing that those with AMD receive and continue their essential treatments, thereby potentially lessening the broader impact of vision-related disabilities in adults.
   

Age-related Macular Degeneration Market Analysis

Based on product, the market is segmented into Eylea, Lucentis, Beovu, Vabysmo, Syfovre, Avastin, and other products. In 2023, Eylea led the market, generating a substantial revenue of USD 4.4 billion.
 

• Eylea, a frontrunner in the global anti-VEGF therapy arena, has been a staple in wet AMD treatment since its FDA approval in 2011. This enduring presence has cultivated immense trust among both healthcare providers and patients, ensuring Eylea's market supremacy even with the advent of newer therapies.
   
• Clinical trials underscore Eylea's robust efficacy, showcasing its capability to maintain or enhance vision in numerous wet AMD patients. Coupled with an established safety profile and consistent clinical results, Eylea has firmly entrenched itself as the go-to treatment for ophthalmologists and patients alike.
   
• According to the European Medicines Agency, Eylea matches ranibizumab in preserving visual acuity for wet AMD patients. Such consistent clinical performance has cemented Eylea's role in AMD treatment protocols.
   
• With approvals for both monthly and bi-monthly dosing, Eylea offers patients tailored flexibility. This adaptability not only boosts convenience but also enhances patient adherence, a crucial factor in managing chronic conditions like AMD.
   
• Eylea's ability to customize treatment frequency to individual needs further underscores its enduring appeal among healthcare providers and patients.
   

Based on disease type, the age-related macular degeneration market is bifurcated into wet AMD and dry AMD. The wet AMD segment dominated the market with the largest revenue of USD 8.5 billion in 2023.
 

• Wet AMD stands as a leading cause of vision impairment in older adults. Characterized by abnormal blood vessel growth beneath the retina, it leads to fluid leakage and central vision damage. Current treatments primarily target the vascular endothelial growth factor (VEGF) to curb blood vessel growth and fluid buildup.
   
• As the global population ages, the incidence of wet AMD is surging. With increasing life expectancy, a growing number of individuals face risks of age-related eye diseases, amplifying the demand for effective vision-preserving treatments. The WHO forecasts a doubling of the global population aged 60 and above, reaching 2.1 billion by 2050, hinting at a potential surge in AMD cases.
   
• Many elderly patients with wet AMD find the frequent need for regular injections, often monthly or bimonthly, to be a significant burden. Innovations like Vabysmo, which may extend the intervals between doses, cater to this need for less frequent treatments. Such advancements not only enhance the quality of life but also ensure better adherence to treatment, especially for those facing mobility or access challenges.
   
• Given these dynamics, the wet AMD segment is poised for substantial growth in the coming years.
   

Based on age group, the age-related macular degeneration market is segmented into 50–64 years, 65–74 years, and 75 and above. The 75 and above segment is projected to reach USD 12.3 billion by 2032.
 

• For patients aged 75 and above, primary treatments for age-related macular degeneration (AMD) encompass anti-VEGF injections, laser therapy, photodynamic therapy, and nutritional supplements. Commonly used anti-VEGF agents like Lucentis, Eylea, and Avastin play a crucial role in preventing vision loss for wet AMD patients.
   
• These agents function by curbing abnormal blood vessel growth and leakage in the retina. In contrast, for the more slowly progressing dry AMD, healthcare providers might suggest lifestyle changes and dietary supplements rich in antioxidants, zinc, and copper to potentially decelerate the disease's progression.
   
• With life expectancy on the rise, the demographic aged 75 and above is expanding rapidly, coinciding with the highest prevalence of AMD. Projections from the UN indicate a tripling of the population aged 80 and older, from 143 million in 2019 to 426 million by 2050. This demographic shift is likely to result in a corresponding uptick in AMD cases, underscoring the urgency for accessible treatments.
   
• Given these trends, the segment is set for notable growth in the foreseeable future.
   

The age-related macular degeneration market is segmented by distribution channel into hospital pharmacies, specialty pharmacies, and E-commerce. In 2023, the hospital pharmacies segment was valued at USD 5.4 billion.
 

• Hospital pharmacies often work hand-in-hand with insurance providers to navigate the financial challenges of AMD treatments, easing the burden on patients. Beyond this, hospitals frequently provide patient assistance programs and financial counseling, a level of support that standalone clinics might lack. This financial backing underscores the pivotal role of hospital pharmacies in the care of AMD patients.
   
• For many older adults grappling with AMD, hospital pharmacies present distinct advantages. Given that these patients often seek various healthcare services within the hospital, the centralized nature of hospital pharmacies streamlines access. This is especially crucial for those with mobility challenges or those who find it difficult to juggle appointments across different venues.
   

In 2023, the U.S. age-related macular degeneration market was valued at USD 4.2 billion, with projections indicating a growth at a CAGR of 9.9% over the forecast period.

• In the U.S., the population aged 65 and older is on the rise, and this demographic is primarily affected by age-related macular degeneration (AMD). Data from the U.S. Census Bureau forecasts that the number of Americans aged 65 and older will nearly double, soaring from 52 million in 2018 to an anticipated 95 million by 2060. This demographic shift significantly drives the demand for AMD treatments, given that the incidence of AMD escalates with age. As the elderly population grows, so too will the cases of AMD, underscoring the need for more advanced and accessible treatment options.
   
• The U.S. leads in biopharmaceutical research and development, making strides in AMD treatments. Major pharmaceutical companies and research institutions in the U.S. are at the forefront, developing advanced treatments for AMD, including gene therapies, extended-release formulations, and combination therapies. This vibrant research landscape solidifies the U.S.'s position as a pivotal player in crafting innovative AMD treatments, with the potential to enhance patient outcomes globally.
   

From 2024 to 2032, the age-related macular degeneration market in the UK is poised for significant growth.
 

• The National Health Service (NHS) in the UK provides extensive coverage for AMD treatments, encompassing anti-vascular endothelial growth factor (anti-VEGF) injections like Lucentis and Eylea. Thanks to NHS reimbursements, many patients can access these effective therapies with minimal out-of-pocket costs. This broad accessibility is a key driver for the growth of the AMD treatment market in the UK.
   
• The UK has rolled out several screening and public health initiatives aimed at early AMD detection, especially for high-risk groups. Such proactive measures not only facilitate timely interventions but also boost the demand for AMD treatments, as patients are diagnosed at more manageable stages of the condition.
   
• For example, the NHS offers optical vouchers and provides complimentary eye tests every two years for adults aged 60 and above, bolstering early AMD detection. Given these public health initiatives, the demand for AMD treatments is set to persist in the years ahead.
   

Between 2024 and 2032, Japan's age-related macular degeneration market is set for notable growth.
 

• As of 2023, Japan boasts an average life expectancy of 87.14 years for women and 81.09 years for men, placing it among the global leaders, according to the World Health Organization (WHO).
• This remarkable longevity has birthed a swiftly aging populace, with 29.1% of Japanese citizens aged 65 or older in 2023, as highlighted by the BBC. Given that older adults are more susceptible to ophthalmic disorders like AMD, there's a surging demand for treatments to ensure optimal eye care. This demographic trend is poised to fuel the market's growth in Japan.
   
• Moreover, Japan's national healthcare system offers comprehensive coverage for AMD treatments, including anti-VEGF therapies. Such inclusivity in public health insurance not only boosts patient accessibility but also propels market growth.
   

Saudi Arabia's age-related macular degeneration market is set for significant growth from 2024 to 2032.
 

• Chronic conditions like diabetes, hypertension, and obesity are prevalent in Saudi Arabia. The World Health Organization (WHO) reported a diabetes prevalence of 17.7% in Saudi Arabia in 2021. These chronic conditions heighten the risk of age-related macular degeneration (AMD), especially among the elderly.
   
• The International Diabetes Federation highlights that individuals with diabetes face a greater likelihood of developing AMD than those without. Given the rising chronic disease rates, there's an intensified demand for AMD treatment and preventive measures, underscoring the urgent need for comprehensive eye care services in the nation.
   
• Aligned with its Vision 2030 initiative, the Saudi government is channeling significant investments into healthcare infrastructure. This endeavor aims to broaden access to advanced medical care and specialized treatments. With the establishment of new hospitals, clinics, and diagnostic centers, the accessibility of AMD treatments is set to expand for the Saudi populace.
   

Age-related Macular Degeneration Market Share

The market is characterized by competition, featuring a blend of major global players alongside smaller and medium-sized companies vying for market share. A pivotal strategy in this market revolves around the consistent introduction of innovative products harnessing diverse technologies. Industry giants, wielding significant influence, often spearhead advancements, bolstered by substantial investments in research and development.
 

Furthermore, maneuvers like strategic alliances, acquisitions, and mergers play a crucial role in fortifying market positions and broadening global reach, especially in the face of shifting regulatory landscapes. Meanwhile, smaller vendors carve out their niche by focusing on specific applications to stand toe-to-toe with established players.
 

Age-related Macular Degeneration Market Industry News:

• In July 2024, Genentech, part of the Roche Group, reintroduced Susvimo (ranibizumab injection) 100 mg/mL via ocular implant for intravitreal use. This treatment targets individuals in the U.S. with wet, or neovascular AMD. The relaunch is poised to boost patient access to effective treatments and enhance adherence by reducing injection frequency.
   
• In September 2021, AbbVie and REGENXBIO Inc. forged a partnership to develop and commercialize RGX-314, a promising one-time gene therapy aimed at wet AMD, diabetic retinopathy (DR), and other chronic retinal ailments. As per the collaboration, AbbVie spearheads the clinical development and global commercialization of RGX-314, while REGENXBIO plays a role in U.S. commercialization efforts.
   

Age-related Macular Degeneration Market Companies

Some of the eminent market participants operating in the age-related macular degeneration industry include:

• Adverum Biotechnologies
• Alkeus Pharmaceuticals
• Amgen
• Astellas Pharma
• Bausch Health Companies
• Bayer AG
• Biogen
• Coherus BioSciences
• F. Hoffmann-La Roche
• Kodiak Sciences
• Novartis AG
• Pfizer
• Regeneron Pharmaceuticals
• Sandoz Group AG
• STADA Arzneimittel AG
   

The age-related macular degeneration market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Eylea
• Lucentis
• Beovu
• Vabysmo
• Syfovre
• Avastin
• Other products

Market, By Disease Type

• Wet AMD
• Dry AMD

Market, By Age Group

• 50–64 years
• 65–74 years
• 75 and above

Market, By Distribution Channel

• Hospital pharmacies
• Specialty pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE